Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5

Anesthesiology

Volumn 102, Issue 3, 2005, Pages 550-556

  Klees, Theresa Mariero ^a   Sheffels, Pamela ^b   Thummel, Kenneth E ^b   Kharasch, Evan D ^b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; ALFENTANIL; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 INHIBITOR; DRUG DERIVATIVE; KETOCONAZOLE; N PHENYLPROPIONAMIDE; NORALFENTANIL; PROPIONAMIDE DERIVATIVE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ALLELE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CLEARANCE; ENZYME INHIBITION; ENZYME SUBSTRATE; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME METABOLISM; METABOLITE; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN CONTENT;

ALFENTANIL; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MICROSOMES, LIVER; PHARMACOGENETICS;

EID: 14644402455     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200503000-00012     Document Type: Conference Paper

References (55)

1. Wood M: Variability of human drug response. ANESTHESIOLOGY 1989; 71: 631-4
2. Maitre PO, Vozeh S, Heykants J, Thomson DA, Stanski DR: Population pharmacokinetics of alfentanil: The average dose-plasma concentration relationship and interindividual variability in patients. ANESTHESIOLOGY 1987; 66:13-6
3. Meuldermans W, Van Peer A, Hendrickx J, Woestenborghs R, Lauwers W, Heykants J, Vanden Bussche G, Van Craeyvelt H, Van der Aa P: Alfentanil pharmacokinetics and metabolism in humans. ANESTHESIOLOGY 1988; 69:527-34
4. Kharasch ED, Russell M, Mautz D, Thummel KE, Kunze KL, Bowdle TA, Cox K: The role of cytochrome P450 3A4 in alfentanil clearance: Implications for interindividual variability in disposition and perioperative drug interactions. ANESTHESIOLOGY 1997; 87:36-50
5. Phimmasone S, Kharasch ED: A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. Clin Pharmacol Ther 2001; 70:505-17
6. Kharasch ED, Walker A, Hoffer C, Sheffels P: Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass CYP3A activity: Noninvasive assessment using pupillary miosis. Clin Pharmacol Ther 2004; 76:452-66
7. Lavrijsen KLM, Van Houdt JMG, Van Dyck DMJ, Hendrickx JJJM, Woestenborghs RJH, Lauwers W, Meuldermans WEG, Heykants JJP: Is the metabolism of alfentanil subject to debrisoquine polymorphism? ANESTHESIOLOGY 1988; 69:535-40
8. Yun OH, Wood M, Wood AJJ, Guengerich FP: Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P450 3A4: An explanation of the variable elimination clearance. ANESTHESIOLOGY 1992; 77:467-74
9. Labroo RB, Kharasch ED: Gas chromatographic-mass spectrometric analysis of alfentanil metabolites: Application to human liver microsomal alfentanil biotransformation. J Chromatogr B 1994; 660:85-94
10. Labroo RB, Thummel KE, Kunze KL, Podoll T, Trager WF, Kharasch ED: Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism. Drug Metab Dispos 1995; 23:490-6
11. Kharasch ED, Russell M, Garton K, Lentz G, Bowdle TA, Cox K: Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. ANESTHESIOLOGY 1997; 87:26-35
12. Kharasch ED, Jubert C, Senn T, Bowdle TA, Thummel KT: Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. J Clin Pharmacol 1999; 39:664-9
13. Kharasch ED, Hoffer C, Walker A, Sheffels P: Disposition and miotic effects of oral alfentanil: A potential noninvasive probe for first-pass cytochrome P4503A activity. Clin Pharmacol Ther 2003; 73:199-208
14. Lamba JK, Lin YS, Schuetz EG, Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271-94
15. Wilkinson GR: Cytochrome P4503A (CYP3A) metabolism: Prediction of in vivo activity in humans. J Pharmacokin Biopharm 1996; 24:475-90
16. Thummel KE, Wilkinson GR: In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998; 38:389-430
17. Dresser GK, Spence JD, Bailey DG: Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38:41-57
18. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR: Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5:243-72
19. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA: Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002; 30:883-91
20. Patki KC, Von Moltke LL, Greenblatt DJ: In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: Role of CYP3A4 and CYP3A5. Drug Metab Dispos 2003; 31:938-44
21. Cook CS, Berry LM, Kim DH, Burton EG, Hribar JD, Zhang L: Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: Differential metabolism by CYP3A4 and CYP3A5. Drug Metab Dispos 2002; 30:1344-51
22. Kalgutkar AS, Taylor TJ, Venkatakrishnan K, Isin EM: Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab Dispos 2003; 31:243-9
23. Shen L, Fitzloff JF, Cook CS: Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3AS. Drug Metab Dispos 2004; 32:186-96
24. Wandel C, Bocker R, Bohrer H, Browne A, Rugheimer E, Martin E: Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 1994; 73:658-61
25. Gorski JC, Hall SD, VandenBranden M, Wrighton SA, Jones DR: Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994; 47:1643-53
26. Gillam EMJ, Guo Z, Ueng Y-F, Yamazaki H, Cock I, Reilly PEB, Hooper WD, Guengerich FP: Expression of cytochrome P450 3A5 in Escherichia coli: Effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. Arch Biochem Biophys 1995; 317:374-84
27. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383-91
28. Wilkinson GR: Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: Some answers but still questions. Clin Pharmacol Ther 2004; 76:99-103
29. Burk O, Wojnowski L: Cytochrome P450 3A and their regulation. Naunyn Schmiedebergs Arch Pharmacol 2004; 369:105-24
30. Williams JA, Cook J, Hurst SI: A significant drug-metabolizing role for CYP3A5? Drug Metab Dispos 2003; 31:1526-30
31. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, Thummel KE: Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62:162-72
32. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, Ingelman-Sundberg M: Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYPA5 in drug metabolism. Drug Metab Dispos 2003; 31:755-61
33. Thummel KE: Does the CYP3A5*3 polymorphism affect in vivo drug elimination? Pharmacogenetics 2003; 13:585-7
34. Guitton J, Buronfosse T, Désage M, Lepape A, Brazier JL, Beaune P: Possible involvement of multiple cytochrome P450s in fentanyl and sufentanil metabolism as opposed to alfentanil. Biochem Pharmacol 1997; 53:1613-9
35. Klees TM, Sheffels P, Dale O, Kharasch ED: Pharmacogenetic and kinetic determinants of alfentanil metabolism by expressed cytochrome P4503A (abstract). ANESTHESIOLOGY 2004; 101:A-1610
36. Gibbs MA, Thummel KE, Shen DD, Kunze KL: Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: Comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 1999; 27:180-7
37. McConn DJ, II, Lin YS, Allen K, Kunze KL, Thummel KE: Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab Dispos 2004; 32:1083-91
38. Chang TKH, Gonzalez FJ, Waxman DJ: Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 1994; 311: 437-42
39. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsui M: Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 1996; 26:681-93
40. Dai Y, Iwanaga K, Lin YS, Hebert MF, Davis CL, Huang W, Kharasch ED, Thummel KE: In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol 2004; 68:1889-902
41. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA: Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989; 36:89-96
42. Kamdem LK, Meineke I, Koch I, Zanger UM, Brockmoller J, Wojnowski L: Limited contribution of CYP3A5 to the hepatic 6β-hydroxylation of testosterone. Naunyn Schmiedebergs Arch Pharmacol 2004; 370:71-7
43. Shih PS, Huang JD: Pharmacokinetics of midazolam and 1′- hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 2002; 30:1491-6
44. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr, Bhat K, Kim RB, Wilkinson GR: Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 2003; 13:595-606
45. Eap CB, Buclin T, Hustert E, Bleiber G, Golay KP, Aubert AC, Baumann P, Telenti A, Kerb R: Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur J Clin Pharmacol 2004; 60:231-6
46. Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Schuetz E, Lim R, Lim HL, Ong AB, Lee HS: Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002; 20:3683-90
47. Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, Gurney H: CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther 2004; 75:529-38
48. Fukuda T, Onishi S, Fukuen S, Ikenaga Y, Ohno M, Hoshino K, Matsumoto K, Maihara A, Momiyama K, Ito T, Fujio Y, Azuma J: CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers. Pharmacogenomics J 2004; 4:34-9
49. Haufroid V, Mourid M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, Wallemacq P: The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14:147-54
50. Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, Legendre C, Daly AK: Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003; 76:1233-5
51. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T: Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74:245-54
52. Macphee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, Goldberg L, Holt DW: Tacrolimus pharmacogenetics: Polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74:1486-9
53. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, Boyle G, Law Y, Miller S, Lamba J, Burckart GJ: Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 2003; 3:477-83
54. Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, Okuda M, Tanaka K, Inui K: CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 2004; 14:471-8
55. MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, Goldberg L, Holt DW: The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004; 4:914-9